CSL Reduces R&D Department, Increases External Alliances
PorAinvest
miércoles, 16 de julio de 2025, 3:53 am ET1 min de lectura
CSL--
CSL, which was founded more than a century ago as a government laboratory focusing on manufacturing vaccines, has invested around $5.8 billion in its R&D division over the last five fiscal years. The company's most profitable business, CSL Behring, is underpinned by this significant investment. The downsizing plan is aimed at streamlining operations and boosting efficiency [2].
The company stated that it is reorganizing its R&D structure to foster collaboration, reduce duplication, and improve efficiencies. A spokesperson for CSL noted that the company will increasingly depend on a more optimal mix of internal capabilities and external partnerships to build and deliver its R&D pipeline, which will necessitate a smaller global internal workforce in the future [1][2].
CSL continues to expect annualized double-digit earnings growth over the medium term, despite a slowdown in profit growth in the first half of fiscal 2025. The company will disclose further details of its R&D downsizing plan in its full-year results on August 19 [2].
References:
[1] https://seekingalpha.com/news/4467518-csl-will-reduce-its-rd-department-increase-external-alliances-reuters
[2] https://www.marketscreener.com/quote/stock/CSL-LIMITED-6492492/news/Australian-biotech-CSL-to-trim-R-D-division-rely-on-external-partnerships-50499348/
CSL Ltd, an Australian biotechnology firm, plans to downsize its research and development (R&D) department across six international sites and increase its reliance on external collaborations. This move follows a report by Reuters on Tuesday. The exact details of the downsizing plan and external partnerships are not specified.
Australian biotechnology firm CSL Ltd has announced plans to downsize its research and development (R&D) division across six international sites and increase its reliance on external collaborations. This move follows a report by Reuters on Tuesday. The exact details of the downsizing plan and external partnerships are not specified [1][2].CSL, which was founded more than a century ago as a government laboratory focusing on manufacturing vaccines, has invested around $5.8 billion in its R&D division over the last five fiscal years. The company's most profitable business, CSL Behring, is underpinned by this significant investment. The downsizing plan is aimed at streamlining operations and boosting efficiency [2].
The company stated that it is reorganizing its R&D structure to foster collaboration, reduce duplication, and improve efficiencies. A spokesperson for CSL noted that the company will increasingly depend on a more optimal mix of internal capabilities and external partnerships to build and deliver its R&D pipeline, which will necessitate a smaller global internal workforce in the future [1][2].
CSL continues to expect annualized double-digit earnings growth over the medium term, despite a slowdown in profit growth in the first half of fiscal 2025. The company will disclose further details of its R&D downsizing plan in its full-year results on August 19 [2].
References:
[1] https://seekingalpha.com/news/4467518-csl-will-reduce-its-rd-department-increase-external-alliances-reuters
[2] https://www.marketscreener.com/quote/stock/CSL-LIMITED-6492492/news/Australian-biotech-CSL-to-trim-R-D-division-rely-on-external-partnerships-50499348/
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios